Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nippon Kayaku’s Humira Biosimilar Adds nr-axSpA Use
Nippon Kayaku said on March 19 that its biosimilar versions of the anti-TNF-α monoclonal antibody Humira (adalimumab) is now approved for an additional indication of non-radiographic axial spondyloarthritis (nr-axSpA) in Japan. The label expansion was granted to Adalimumab BS Subcutaneous…
To read the full story
Related Article
- Nippon Kayaku’s Humira Biosimilar Adds Pediatric UC Use
March 26, 2026
- Nippon Kayaku Files Humira Biosimilar for nr-axSpA
October 1, 2024
- Humira Filed for nr-axSpA in Japan Based on Public Knowledge: AbbVie
September 2, 2024
BUSINESS
- Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
- Shionogi Signs US Government Contract to Boost Cefiderocol Supply
April 9, 2026
- Sumitomo Pharma to Raise up to 116.5 Billion Yen for R&D, Debt Reduction
April 9, 2026
- Meiji Pharma Asia Launches Operations in Singapore
April 9, 2026
- Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…